Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Liabilities: 2024-2025

Historic Other Non-Current Liabilities for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $3.1 million.

  • Krystal Biotech's Other Non-Current Liabilities rose 312.22% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 312.22%. This contributed to the annual value of $1.4 million for FY2024, which is N/A change from last year.
  • Krystal Biotech's Other Non-Current Liabilities amounted to $3.1 million in Q3 2025, which was up 12.04% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Other Non-Current Liabilities peaked at $3.1 million during Q3 2025, and registered a low of $588,000 during Q2 2024.
  • In the last 2 years, Krystal Biotech's Other Non-Current Liabilities had a median value of $1.7 million in 2024 and averaged $1.8 million.
  • Data for Krystal Biotech's Other Non-Current Liabilities shows a peak YoY soared of 376.19% (in 2025) over the last 5 years.
  • Over the past 2 years, Krystal Biotech's Other Non-Current Liabilities (Quarterly) stood at $1.4 million in 2024, then skyrocketed by 312.22% to $3.1 million in 2025.
  • Its Other Non-Current Liabilities was $3.1 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.0 million in Q1 2025.